8 November 2017 - Bayer’s Stivarga is not being recommended by NHS treatment cost regulators for certain patients with advanced unresectable hepatocellular carcinoma.

The National Institute for Health and Care Excellence has published an appraisal consultation document rejecting use of Stivarga (regorafenib) in adults who have had already had access to sorafenib.

Currently, for people who cannot tolerate sorafenib, or whose disease progresses on the drug, the only other option in the UK is best supportive care.

Read Pharma Times article